Nuclear Receptor COUP-TFII Controls Pancreatic Islet Tumor Angiogenesis by Regulating Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Signaling
- 31 October 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (21) , 8812-8821
Abstract
The significance of angiogenesis in cancer biology and therapy is well established. In this study, we used the prototypical RIP-Tag model of multistage pancreatic islet tumorigenesis to show that the nuclear receptor COUP-TFII is essential to regulate the balance between pro- and anti-angiogenic molecules that influence the angiogenic switch in cancer. Conditional ablation of COUP-TFII in the tumor microenvironment severely compromised neoangiogenesis and lymphangiogenesis during pancreatic tumor progression and metastasis. We found that COUP-TFII plays a cell-autonomous role in endothelial cells to control blood vessel sprouting by regulating cell proliferation and migration. Mechanistic investigations revealed that COUP-TFII suppressed vascular endothelial growth factor (VEGF)/VEGF receptor-2 (VEGFR-2) signaling by transcriptionally repressing the expression of VEGFR-1, thereby curtailing a central angiogenic driver of vascular growth. Taken together, our results implicate COUP-TFII as a critical factor in tumor angiogenesis through regulation of VEGF/VEGFR-2 signaling, suggesting COUP-TFII as a candidate target for antiangiogenic therapy. Cancer Res; 70(21); 8812–21. ©2010 AACR.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel developmentJournal of Clinical Investigation, 2010
- The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cellsGenes & Development, 2010
- COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesisProceedings of the National Academy of Sciences, 2010
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangiomaNature Medicine, 2008
- The biology of VEGF and its receptorsNature Medicine, 2003
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989